The Company capitalizes its purchases of saleable inventory of VASCEPA from suppliers that have been qualified by the U.S. FDA and other global regulatory agencies. Inventory is comprised of raw materials, work in progress, and finished goods. Raw materials include purchased components and materials used in the manufacturing process, primarily API. Work in process consists of products in various stages of production. Finished goods represent completed products available for sale, VASCEPA, in 1-gram or 0.5-gram capsules. API currently has a shelf life of between four and five years. After being converted into capsule form, which is the last step in the manufacturing process, VASCEPA 1-gram and 0.5-gram capsules have remaining shelf lives of four to five years, with the approved shelf life varying by jurisdiction based on local regulatory approvals. Inventories as of September 30, 2026 and December 31, 2025 consist of the following:


In thousands	September 30, 2026		December 31, 2025
Raw materials	$	109,418	$	112,291
Work in process		14,276		8,201
Finished goods		35,156		75,418
Total inventory (1)	$	158,850	$	195,910

(1) During the three and nine months ended September 30, 2026, approximately $0.3 million and $2.0 million, respectively, of inventory was expensed through cost of goods sold for both product and non-product dating inventory. During the nine months ended September 30, 2025, approximately $0.4 million of inventory was expensed through cost of goods sold for product dating inventory.